EP1272512A4 - Composition d'immunokine et methode associee - Google Patents

Composition d'immunokine et methode associee

Info

Publication number
EP1272512A4
EP1272512A4 EP01922384A EP01922384A EP1272512A4 EP 1272512 A4 EP1272512 A4 EP 1272512A4 EP 01922384 A EP01922384 A EP 01922384A EP 01922384 A EP01922384 A EP 01922384A EP 1272512 A4 EP1272512 A4 EP 1272512A4
Authority
EP
European Patent Office
Prior art keywords
immunokine
composition
immunokine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01922384A
Other languages
German (de)
English (en)
Other versions
EP1272512A2 (fr
Inventor
David D Mundschenk
Paul F Reid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PhyloMed Corp
Original Assignee
PhyloMed Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PhyloMed Corp filed Critical PhyloMed Corp
Publication of EP1272512A2 publication Critical patent/EP1272512A2/fr
Publication of EP1272512A4 publication Critical patent/EP1272512A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP01922384A 2000-03-23 2001-03-14 Composition d'immunokine et methode associee Withdrawn EP1272512A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US533454 1990-06-05
US53345400A 2000-03-23 2000-03-23
PCT/US2001/008150 WO2001070173A2 (fr) 2000-03-23 2001-03-14 Composition d'immunokine et methode associee

Publications (2)

Publication Number Publication Date
EP1272512A2 EP1272512A2 (fr) 2003-01-08
EP1272512A4 true EP1272512A4 (fr) 2003-05-07

Family

ID=24126023

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01922384A Withdrawn EP1272512A4 (fr) 2000-03-23 2001-03-14 Composition d'immunokine et methode associee

Country Status (4)

Country Link
EP (1) EP1272512A4 (fr)
AU (1) AU2001249194A1 (fr)
CA (1) CA2404078A1 (fr)
WO (1) WO2001070173A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2656992A1 (fr) 2006-07-03 2008-01-10 Inagen Aps Immunotoxines pour traiter des maladies associees a une i nfection par le cytomegalovirus (cmv)
US7259237B1 (en) 2006-12-29 2007-08-21 Miller Kent D Pan-antiviral peptides
US9220743B2 (en) 2010-01-22 2015-12-29 Nuovo Biologics, Llc Pan-antiviral peptides for protein kinase inhibition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028258A1 (fr) * 1996-01-30 1997-08-07 The National Institutes Of Health Cellules exprimant les molecules humaines cd4 et cxcr4
FR2751658A1 (fr) * 1996-07-26 1998-01-30 Pasteur Institut Utilisation d'une chemokine (sdf-1) ligand pour le recepteur de lestr/fusin/cxcr4 pour prevenir ou traiter l'infection par des virus de type vih
WO1998051705A1 (fr) * 1997-05-12 1998-11-19 Fondazione Centro San Raffaele Del Monte Tabor Peptides presentant une activite antivirale

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0912726A4 (fr) * 1996-05-10 2001-07-18 Phylomed Corp Procedes permettant d'oxyder des liaisons bisulfure avec de l'ozone
US5994515A (en) * 1996-06-25 1999-11-30 Trustees Of The University Of Pennsylvania Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028258A1 (fr) * 1996-01-30 1997-08-07 The National Institutes Of Health Cellules exprimant les molecules humaines cd4 et cxcr4
FR2751658A1 (fr) * 1996-07-26 1998-01-30 Pasteur Institut Utilisation d'une chemokine (sdf-1) ligand pour le recepteur de lestr/fusin/cxcr4 pour prevenir ou traiter l'infection par des virus de type vih
WO1998051705A1 (fr) * 1997-05-12 1998-11-19 Fondazione Centro San Raffaele Del Monte Tabor Peptides presentant une activite antivirale

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OBERLIN E ET AL: "THE CXC CHEMOKINE SDF-1 IS THE LIGAND FOR LESTR/FUSIN AND PREVENTS INFECTION BY T-CELL-LINE-ADAPTED HIV-1", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 382, no. 6594, 29 August 1996 (1996-08-29), pages 833 - 835, XP002028004, ISSN: 0028-0836 *
See also references of WO0170173A3 *

Also Published As

Publication number Publication date
EP1272512A2 (fr) 2003-01-08
WO2001070173A2 (fr) 2001-09-27
CA2404078A1 (fr) 2001-09-27
WO2001070173A3 (fr) 2002-03-14
AU2001249194A1 (en) 2001-10-03

Similar Documents

Publication Publication Date Title
AU6832101A (en) Composition and method
AU5752601A (en) Splice-region antisense composition and method
GB0008264D0 (en) Novel method and compounds
EG23122A (en) Pyrrolcarboxamides and pyrrolcarbothioamides
AU4163402A (en) Composition and method
AU9667901A (en) Mycoattractants and mycopesticides
EP1313477A4 (fr) Composes et procedes
EP1274424A4 (fr) Composes et procedes
SG94358A1 (en) Polishing composition and method
AP2001002305A0 (en) Improved prosthesis and method thereof
AU7311501A (en) Cosmetic composition and method
HU0104832D0 (en) Cosmetic composition and method
GB0014185D0 (en) Compound and method
GB0126643D0 (en) Composition and process
AU2001233932A1 (en) Method and composition
GB0014580D0 (en) Appatarus and process
AU2002239775A1 (en) Chemical-library composition and method
AU7220501A (en) Mortar composition and method
EP1343796A4 (fr) Composes et procedes
EP1272512A4 (fr) Composition d'immunokine et methode associee
GB0107033D0 (en) Method and composition
SG88779A1 (en) Food modification method and composition therefor
AU5104101A (en) Composition and use
GB0121627D0 (en) Method and composition
GB0111734D0 (en) Composition and method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021023

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 38/00 B

Ipc: 7C 07K 14/46 A

Ipc: 7A 61K 39/395 B

A4 Supplementary search report drawn up and despatched

Effective date: 20030325

17Q First examination report despatched

Effective date: 20031008

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20060125